ArticleJournal of dental sciences2026
Synergistic effect of combined cisplatin and rosmarinic acid on apoptosis and migration of head and neck cancer cell lines.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Rosmarinic acid (RA), a phenolic compound demonstrating therapeutic effects including anticancer properties. Cisplatin, a chemotherapeutic agent, is widely employed in cancer treatment. Head and neck squamous cell carcinoma (HNSCC) exhibits high mortality rates, frequently resistance to cisplatin-based regimens. Cisplatin and RA combination enhanced cisplatin efficiency across various tumor types. This study aimed to elucidate the effects of cisplatin-RA combination on cell proliferation, apoptosis and migration in HNSCC cell lines. Materials and methods: Primary HNSCC cell lines (HN18/HN30) and metastatic HNSCC cell lines (HN17/HN31) were employed in this investigation. Cells underwent treatment with rosmarinic acid (100-1,000 μM) or cisplatin (5-40 μM) for 72 h, followed by cell viability assessment using MTT assay. The combinatorial cisplatin-RA treatment effects on cell proliferation inhibition were quantified using MTT assay, with calculation of the combination index to assess synergistic interactions. Synergistic effects of cisplatin-RA combination on apoptosis and cell migration were evaluated in HNSCC cell lines through flow cytometric analysis and scratch assay, respectively. Results: Both cisplatin and rosmarinic acid demonstrated concentration-dependent reductions in HNSCC cell viability. Combination index of cisplatin-RA interaction indicating synergistic interactions in HN17, HN30 and HN31 cells. Cisplatin (20 μM) with RA (400 μM) combination synergistically induced apoptosis in HN18 and HN17 cells, while cisplatin (20 μM) and RA (800 μM) combination demonstrated synergistic apoptotic induction in HN30 and HN31 cells. Cisplatin and RA monotherapy, but not combination significantly inhibited HNSCC cell migration. Conclusion: This study found that cisplatin-RA combination can inhibit proliferation and induce apoptosis in HNSCC cell lines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.